Full Press Release Details
TransMedics Reports First Quarter 2020 Financial Results
Andover, Mass. May 06, 2020 (GLOBE NEWSWIRE) TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology
company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended March 31, 2020.
We began 2020 with strong momentum and remain extremely confident in TransMedics long-term prospects, said Waleed Hassanein, MD, President
and Chief Executive Officer. We continue to lean forward throughout this COVID-19 pandemic to establish and broaden our technological and clinical service offering to facilitate organ procurement and transplantation using our OCS Technology
during and in the post-COVID era. We have also taken extensive measures to preserve cash and mitigate business and health risks on our organization and team. Finally, I want take a moment to thank the transplant healthcare workers and TransMedics
team on the frontline during this pandemic who are ensuring that organ transplants procedures are continuing to help patients in need.
Quarter 2020 Financial Results
Net revenue for the first quarter of 2020 was $7.5 million, a 61% increase compared to $4.7 million in the
first quarter of 2019. The increase was driven by OCS adoption in several areas including US OCS Lung commercial adoption, US clinical trials for OCS Heart and OCS Liver, as well as international OCS Heart.
Gross margin for the first quarter of 2020 was 65% as compared to 55% in the first quarter of 2019.
Operating expenses for the first quarter of 2020 were $12.9 million compared to $8.5 million in the first quarter of 2019. The increase in operating
expenses was driven by higher SG&A costs stemming from investments in our commercial team and costs associated with being a public company. In addition, costs associated with supporting clinical trials and product development drove R&D
expenses as compared to the first quarter of 2019.
Net loss for the first quarter of 2020 was $8.9 million compared to $6.9 million in the
first quarter of 2019.
Cash, cash equivalents and marketable securities were $72.6 million as of March 31, 2020.
2020 Financial Outlook
As previously announced, on April
13, 2020, TransMedics withdrew its annual guidance for 2020 due to the unpredictability of the duration and the magnitude of the impact that the COVID-19 pandemic will have on its financial and operating results.
Webcast and Conference Call Details
The TransMedics management team will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6, 2020. Investors interested in
listening to the conference call may do so by dialing (866) 221-1172 for domestic callers or (270) 215-9603 for international callers, followed by Conference ID:
4939519. A live and archived webcast of the event will be available on the Investors section of the TransMedics website at www.transmedics.com.
About TransMedics Group, Inc.
world s leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for
transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage
heart, lung and liver failure.
Forward-Looking Statements
This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including
statements about our results of operations, commercial opportunity and the rate of adoption and benefits of the OCS. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those
expressed or implied in such statement. Applicable risks and uncertainties include those related to our anticipation that we continue to incur losses; our need to raise additional funding; our existing and any future indebtedness, including our
ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject to until maturity, and our ability to obtain additional financing on favorable terms or at all; the fluctuation of our financial
results from quarter to quarter; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the OCS; the rate and degree of market acceptance of the OCS; our ability to educate
patients, surgeons, transplant centers and private payors of benefits offered by the OCS; the impact of the outbreak of the novel strain of coronavirus and associated containment and remediation efforts; our ability to improve the OCS platform; our
dependence on a limited number of customers for a significant portion of our net revenue; the timing of and our ability to obtain and maintain regulatory approvals or clearances for our OCS products; our ability to adequately respond to FDA follow-up inquiries in a timely manner; the performance of our third-party suppliers and manufacturers; the timing or results of clinical trials for the OCS; our manufacturing, sales, marketing and clinical support
capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to attract and retain key personnel; our ability to protect, defend,
maintain and enforce our intellectual property rights relating to the OCS and
avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; our ability to obtain and maintain regulatory approvals or
clearance for our OCS products; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and
success of competing products that are or may become available; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and the risks identified under the
heading Risk Factors and elsewhere in our annual report on Form 10-K for the year ended December 28, 2019, which is available on the SEC s website at www.sec.gov. Additional information
will be made available by our annual and quarterly reports and other filings that we make from time to time with the SEC. These forward-looking statements (except as otherwise noted) speak only as of the date of this presentation. Factors or events
that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future
developments or otherwise, except as may be required by applicable law.
TransMedics Group, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
| Fiscal Three Months Ended | ||||||||
| March 31, 2020 | March 30, 2019 | |||||||
| Net revenue | $ | 7,530 | $ | 4,676 | ||||
| Cost of revenue | 2,670 | 2,103 | ||||||
| Gross profit | 4,860 | 2,573 | ||||||
| Gross Margin | 65 | % | 55 | % | ||||
| Operating expenses: | ||||||||
| Research, development and clinical trials | 6,225 | 3,882 | ||||||
| Selling, general and administrative | 6,652 | 4,653 | ||||||
| Total operating expenses | 12,877 | 8,535 | ||||||
| Loss from operations | (8,017 | ) | (5,962 | ) | ||||
| Other income (expense): | ||||||||
| Interest expense | (1,042 | ) | (1,093 | ) | ||||
| Change in fair value of preferred stock warrant liability | 273 | |||||||
| Other income (expense), net | 217 | (103 | ) | |||||
| Total other expense, net | (825 | ) | (923 | ) | ||||
| Loss before income taxes | (8,842 | ) | (6,885 | ) | ||||
| Provision for income taxes | (10 | ) | (10 | ) | ||||
| Net loss | $ | (8,852 | ) | $ | (6,895 | ) | ||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.42 | ) | $ | (4.86 | ) | ||
| Weighted average common shares outstanding, basic and diluted | 21,221,385 | 1,418,353 | ||||||
| * Reconciliation of Gross to Net revenue for certain payments made to customers (in thousands) | ||||||||
| Fiscal Three Months Ended | ||||||||
| March 31, 2020 | March 30, 2019 | |||||||
| Gross revenue from sales to customers | $ | 8,243 | $ | 5,290 | ||||
| Less: clinical trial payments reducing revenue | 713 | 614 | ||||||
| Total net revenue | $ | 7,530 | $ | 4,676 |
TransMedics Group, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| March 31, 2020 | December 28, 2019 | |||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 24,738 | $ | 20,092 | ||||
| Marketable securities | 47,816 | 60,596 | ||||||
| Accounts receivable | 6,133 | 6,559 | ||||||
| Inventory | 11,361 | 11,216 | ||||||
| Prepaid expenses and other current assets | 1,656 | 1,538 | ||||||
| Total current assets | 91,704 | 100,001 | ||||||
| Property and equipment, net | 4,713 | 4,792 | ||||||
| Restricted cash and other long-term assets | 506 | 506 | ||||||
| Total assets | $ | 96,923 | $ | 105,299 | ||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,860 | $ | 7,247 | ||||
| Accrued expenses and other current liabilities | 9,926 | 8,332 | ||||||
| Deferred revenue | 164 | 166 | ||||||
| Current portion of deferred rent | 89 | 370 | ||||||
| Total current liabilities | 15,039 | 16,115 | ||||||
| Long-term debt, net of discount | 34,269 | 34,146 | ||||||
| Deferred rent, net of current portion | 932 | 389 | ||||||
| Total liabilities | 50,240 | 50,650 | ||||||
| Total stockholders equity | 46,683 | 54,649 | ||||||
| Total liabilities and stockholders equity | $ | 96,923 | $ | 105,299 |